Biopharmaceuticals and therapeutic proteins produced by recombinant DNA technology, are now the most rapidly growing class of new therapeutic agents. THD funding will be used to establish a national biopharmaceutical facility able to produce recombinant proteins from a range of expression systems and in sufficient quantities and purities to allow researchers to carry out pre-clinical evaluation and testing of the protein. Termed the National Biopharmaceuticals Facility (NBF), the facility will be based on the existing infrastructure for protein production at the Australian Institute for Bioengineering and Nanotechnology (AIBN) in Brisbane, and CSIRO in Melbourne.
The new infrastructure will:
• Provide a form of protein expression platforms for the development of biopharmaceuticals.
• Develop monoclonal antibody discovery, expression, and conjugation platforms
The infrastructure developed will include the development of tested GMP cell banks of Chinese hamster ovary (CHO) cells, and CHO cell hosts that will be capable of building glycans of specific structure.